BUY LETROZOLE 25 (FEMARA) (2.5 MG/TAB. – 30 TABS)

Main Description

Letrozole 25 is an oral tablet containing 2.5 mg of letrozole, a third-generation, non-steroidal aromatase inhibitor. According to the supplied product information, letrozole works by selectively and reversibly inhibiting the aromatase enzyme, which is responsible for the conversion of androgen precursors such as androstenedione and testosterone into oestrogens including oestrone and oestradiol.

By reducing peripheral oestrogen production, letrozole can reduce oestrogen-mediated stimulation in hormone-dependent breast cancer. The supplied information therefore identifies letrozole primarily for use in postmenopausal women with certain forms of breast cancer, including extended adjuvant treatment following tamoxifen therapy and the treatment of locally advanced, metastatic or advanced disease in specified circumstances.

The product contains letrozole as its active ingredient and is formulated as an oral tablet. Each tablet contains 2.5 mg of letrozole. The supplied product information gives the molecular formula as C17HNS, a molecular weight of 285.31 g/mol and CAS number 11280951-5.

Key Product Information

• Product: Letrozole 25 (Femara)
• Strength: 2.5 mg per tablet
• Active ingredient: Letrozole
• Dosage form: Tablet
• Route: Oral
• Pack size: 30 tablets
• CAS number: 11280951-5
• Market status: Prescription
• Company: Hilma Biocare

Pharmacological Profile

Letrozole reduces oestrogen synthesis by inhibiting aromatase. The supplied information reports that measurable suppression of plasma oestrone and oestradiol occurs following administration, with maximum suppression reported approximately 48–78 hours after dosing. In postmenopausal women with advanced breast cancer, daily letrozole has been associated with substantial suppression of circulating oestrogen concentrations.

The supplied information also states that letrozole does not significantly affect circulating androgen concentrations at the studied doses in healthy postmenopausal women and does not significantly alter thyroid function. Its pharmacological activity is therefore principally associated with suppression of oestrogen biosynthesis through aromatase inhibition.

Indications

The supplied product information lists letrozole for:

• Extended adjuvant treatment of early breast cancer in postmenopausal women following five years of adjuvant tamoxifen therapy.
• First-line treatment of certain hormone-receptor-positive or hormone-receptor-unknown locally advanced or metastatic breast cancers in postmenopausal women.
• Treatment of advanced breast cancer following progression after anti-oestrogen therapy.

Treatment duration depends on the clinical setting and should be determined by the prescribing physician.

Warnings and Precautions

Letrozole is contraindicated in patients with hypersensitivity to the active substance or excipients. The supplied information also lists premenopausal endocrine status, pregnancy and breastfeeding as contraindications.

Because letrozole substantially lowers oestrogen levels, it can affect bone health. Patients with osteoporosis, previous fractures or an increased risk of osteoporosis may require assessment of bone mineral density before treatment and monitoring during and after therapy.

Patients with severe hepatic impairment require close medical supervision. The supplied information also recommends determining menopausal status where it is unclear before treatment.

Letrozole may cause fatigue, dizziness or somnolence in some patients. Caution is therefore advised when driving or operating machinery if these effects occur.

Adverse Reactions

Reported adverse reactions include arthralgia, bone fracture, oedema, dizziness, fatigue, hypercholesterolaemia, osteoporosis and flushing. Other reported effects include myalgia, breast pain, chest pain, depression, chills, fever and swelling of the feet or lower legs.

Patients should discuss persistent, severe or unexpected symptoms with their healthcare professional.

Drug Interactions

The supplied information advises caution with tamoxifen, other anti-oestrogens and oestrogen-containing therapies because these medicines may reduce the pharmacological action or plasma concentration of letrozole. Letrozole metabolism involves CYP2A6 and CYP3A4, and interactions with medicines affecting these pathways may require medical consideration.

Dosage and Administration

The supplied product information gives a recommended dose of one 2.5 mg tablet once daily, with or without food. Treatment should follow the prescribing physician’s instructions. The supplied information reports a half-life of approximately two days.

Do not alter the prescribed dose or treatment duration without medical advice.

Storage

Store between 15–25°C and protect from light.